AC
EVGN icon

Armistice Capital’s Evogene EVGN Stock Holding History

Armistice Capital’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-456,587
Closed -$352K – 360
2026
Q1 		$352K Buy
+456,587
New +$431K 0.01% 186
2025
Q2 		– Sell
-316,024
Closed -$395K – 224
2025
Q1 		$395K Buy
316,024
+17,743
+6% +$26.8K 0.01% 184
2024
Q4 		$558K Buy
298,281
+103,589
+53% +$204K 0.01% 176
2024
Q3 		$598K Buy
+194,692
New +$840K 0.01% 185

Other funds holding EVGN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Armistice Capital's EVGN Position: Q2 2026 in Review

Armistice Capital sold out of Evogene (EVGN) in Q2 2026, closing a stake of 456,587 shares — an estimated $352K sold.

Armistice Capital first reported a position in EVGN in Q3 2024 and held it in 4 quarters. The position peaked at $598K in Q3 2024. 13 funds tracked by Wall St. Rank hold EVGN as of Q2 2026.

  • Armistice Capital reported no remaining Evogene position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 456,587 Evogene shares in Q2 2026, an estimated $352K.
  • Armistice Capital first reported a position in Evogene in Q3 2024 and held it in 4 quarters.
  • Armistice Capital's Evogene position peaked at $598K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held Evogene as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.